QT Imaging Holdings, Inc. (QTI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 9, 2025, by QT Imaging Holdings, Inc., a Delaware corporation and emerging growth company. The filing details a definitive material agreement entered into on April 9, 2025, regarding a private placement of securities. The Company's common stock, previously traded on Nasdaq under the symbol "QTI," was delisted and suspended on January 28, 2025. Trading subsequently resumed on the OTCQB Venture Market under the symbol "QTIH" on March 11, 2025.
Key Financial Metrics and Transaction Details
The filing discloses a private placement transaction with the following specific financial terms:
- Aggregate Gross Proceeds: Approximately $500,000.
- Securities Issued: 784,929 shares of Common Stock and one Common Stock Purchase Warrant.
- Purchase Price: $0.637 per share (110% of the volume-weighted trading price on April 9, 2025).
- Warrant Terms: Exercisable for 1,569,858 shares at $0.72 per share; exercisable beginning 6 months after issuance with a 10-year term.
- Use of Proceeds: Net proceeds are designated for working capital purposes.
- Offering Expenses: Consist solely of legal fees payable by the Company.
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement with Dr. Avi Katz (Chairman) and Dr. Raluca Dinu (CEO). Key contractual obligations include:
- Restrictions on Proceeds: Funds cannot be used for the redemption of Common Stock or Common Stock Equivalents, nor in violation of the Foreign Corrupt Practices Act or OFAC regulations.
- Registration Rights: The Company must file a registration statement for the resale of securities within 30 days of the agreement and have it declared effective within 60 days (or 90 days in the event of a full SEC review).
- Liquidated Damages: If the Company fails to allow resales for more than 10 consecutive days or 20 aggregate days in a 12-month period, it must pay the Purchasers 0.5% of the aggregate subscription amount monthly as partial liquidated damages.
- Closing Date: Expected by April 24, 2025.
Outlook, Risks, and Management Commentary
Management intends to use the proceeds to support working capital needs. The filing includes extensive forward-looking statements regarding the commercialization of the QT Imaging Breast Acoustic CT Scanner, product expansion, and strategic partnerships. Significant risks identified include:
- Uncertainty in selling and deploying the Breast Acoustic CT Scanner.
- Delays in product documentation and market entry.
- Fluctuations in industry demand and supplier unpredictability.
- A material weakness in internal controls over financial reporting.
- Ability to obtain future financing and meet debt obligations.
Investor Verification Checklist
- Verify the closing of the private placement by the expected date of April 24, 2025.
- Confirm the filing and effectiveness of the registration statement for the resale of securities within the 60-day window.
- Monitor the Company's liquidity status given the material weakness in internal controls and reliance on working capital financing.
- Review the Company's progress on commercializing the Breast Acoustic CT Scanner as a primary revenue driver.
- Check for any updates regarding the delisting proceedings or trading status on the OTCQB Venture Market.